229
Views
4
CrossRef citations to date
0
Altmetric
Cornea

In Vitro Efficacy of Chlorhexidine and a riboflavin/UVA Combination on Fungal Agents of Keratitis

, , , ORCID Icon, , , & show all
Pages 7-11 | Received 17 Feb 2019, Accepted 31 Jul 2019, Published online: 14 Aug 2019

References

  • Thomas PA, Kaliamurthy J. Mycotic keratitis: epidemiology, diagnosis and management. Clin Microbiol Infect. 2013;19(3):210–20. doi:10.1111/1469-0691.12126.
  • Matsumoto Y, Murat D, Kojima T, Shimazaki J, Tsubota K. The comparison of solitary topical micafungin or fluconazole application in the treatment of Candida fungal keratitis. Br J Ophthalmol. 2011;95(10):1406–09. doi:10.1136/bjo.2010.191734.
  • Kredics L, Narendran V, Shobana CS, Vaglögyi C, Manikandan P. Filamentous fungal infections of the cornea: a global overview of epidemiology and drug sensitivity. Mycoses. 2015;58(4):243–60. doi:10.1111/myc.12306.
  • Garg P, Roy A, Roy S. Update on fungal keratitis. Curr Opin Ophthalmol. 2016;27(4):333–39. doi:10.1097/ICU.0000000000000272.
  • Ng JK, Fraunfelder FW, Winthrop KL. Review and update on the epidemiology, clinical presentation, diagnosis, and treatment of fungal keratitis. Curr Fungal Infect Rep. 2013;7(4):293–300. doi:10.1007/s12281-013-0163-9.
  • Lalitha P, Sun CQ, Prajna NV. In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial. Am J Ophthalmol. 2014;157(2):318–26. doi:10.1016/j.ajo.2013.10.004.
  • Rakeman JL, Bui U, LaFe K, Chen Y-C, Honeycutt RJ, Cookson BT. Multilocus DNA sequence comparisons rapidly identify pathogenic molds. J Clin Microbiol. 2005;43(7):3324–33. doi:10.1128/JCM.43.7.3324-3333.2005.
  • Kalaiselvi G, Narayana S, Krishnan T, Sengupta S. Intrastromal voriconazole for deep recalcitrant fungal keratitis: a case series. Br J Ophthalmol. 2015;99(2):195–98. doi:10.1136/bjophthalmol-2014-305412.
  • Guber I, Bergin C, Majo F. Repeated intrastromal injections of voriconazole in combination with corneal debridement for recalcitrant fungal keratitis - a case series. Klin Monbl Augenheilkd. 2016;233(4):369–72. doi:10.1055/s-0041-111814.
  • McDonald EM, Ram FS, Patel DV, McGheei CN. Effectiveness of topical antifungal drugs in the management of fungal keratitis: A systematic review and meta-analysis of randomized controlled trials. Asia Pac J Ophthalmol (Phila). 2014;3(1):41–47. doi:10.1097/APO.0b013e3182a618dd.
  • Wollensak G, Spörl E, Seiler T. Treatment of keratoconus by collagen cross linking. Ophthalmologe. 2003;100(1):44–49. doi:10.1007/s00347-002-0700-3.
  • Martins SA, Combs JC, Noguera G, Camacho W, Wittmann P, Walther R. Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis. Invest Ophthalmol Vis Sci. 2008;49(8):3402–08. doi:10.1167/iovs.07-0624.
  • Hafezi F, Randleman JB. PACK-CXL: defining CXL for infectious keratitis. J Refract Surg. 2014;30(7):438–39. doi:10.3928/1081597X-20140609-01.
  • Alio JL, Abbouda A, Valle DD, Del Castillo JM, Fernandez JA. Corneal cross-linking and infectious keratitis: a systematic review with a meta-analysis of reported cases. J Ophthalmic Inflamm Inf. 2013;3(1):47. doi:10.1186/1869-5760-3-47.
  • Uddaraju M, Mascarenhas J, Das MR, Radhakrishnan N, Keenan JD, Prajna L, Prajna VN. Corneal cross-linking as an adjuvant therapy in the management of recalcitrant deep stromal fungal keratitis: a randomized trial. Am J Ophthalmol. 2015;160(1):131–34. doi:10.1016/j.ajo.2015.03.024.
  • Tabibian D, Mazzotta C, Hafezi F. PACK-CXL: corneal cross-linking in infectious keratitis. Eye Vis. 2016;3:11. doi:10.1186/s40662-016-0042-x.
  • Samson RA, Visagie CM, Houbraken J, Hong SB, Hubka V, Klaassen CH, Perrone G, Seifert KA, Susca A, Tanney JB, et al. Phylogeny, identification and nomenclature of the genus Aspergillus. Stud Mycol. 2014;78:141–73. doi:10.1016/j.simyco.2014.07.004.
  • Homa M, Shobana CS, Singh YR, Manikandan P, Selvam KP, Kredics L, Narendan V, Vagvolgyi C, Galgoczy L. Fusarium keratitis in South India: causative agents, their antifungal susceptibilities and a rapid identification method for the Fusarium solani species complex. Mycoses. 2013;56(5):501–11. doi:10.1111/myc.12062.
  • Bilgihan K, Kalkanci A, Ozdemir HB, Yazar R, Karakurt F, Yuksel E, Otag F, Karabicak N, Arikan-Akdagli S. Evaluation of antifungal efficacy of 0.1% and 0.25% riboflavin with UVA: A comparative in vitro study. Curr Eye Res. 2016;41(8):1050–56. doi:10.3109/02713683.2015.1088956.
  • Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard. 2nd ed. Wayne (PA, USA): CLSI; 2008.
  • Ortillés Á, Belloc J, Rubio E, Fernandez MT, Benito M, Cristobal JA, Calvo B, Goni P. In vitro development of an effective treatment for Acanthamoeba keratitis. Int J Antimicrob Agents. 2017;50(3):325–33. doi:10.1016/j.ijantimicag.2017.03.033.
  • Sunada A, Kimura K, Nishi I, Toyokawa M, Ueada A, Sakata T, Suzuki T, Inoue Y, Ohashi Y, Asari S, et al. In vitro evaluations of topical agents to treat Acanthamoeba keratitis. Ophthalmology. 2014;121(10):2059–65. doi:10.1016/j.ophtha.2014.04.013.
  • Oliveira Dos Santos C, Kolwijck E, van der Lee HA, Tehupeiory-Kooreman MC, Al-Hatmi AMS, Matayan E, Burton MJ, Eggink CA, Verweij PE. vitro activity of chlorhexidine compared with seven antifungal agents against 98 Fusarium isolates recovered from fungal keratitis patients. Antimicrob Agents Chemother. 2019. doi:10.1128/AAC.02669-18.
  • Vazirani J, Vaddavalli PK. Cross-linking for microbial keratitis. Indian J Ophthalmol. 2013;61(8):441–44. doi:10.4103/0301-4738.116068.
  • Tabibian D, Richoz O, Riat A, Schrenzel J, Hafezi F. Accelerated photoactivated chromophore for keratitis-corneal collagen cross-linking as a first-line and sole treatment in early fungal keratitis. J Refract Surg. 2014;30(12):855–57. doi:10.3928/1081597X-20141113-06.
  • Hao ZQ, Song JX, Pan SY, Zhang L, Cheng Y, Liu XN, Wu J, Xiao XH, Gao W, Zhu HF. Corneal collagen cross-linking and liposomal amphotericin B combination therapy for fungal keratitis in rabbits. Int J Ophthalmol. 2016;9:1549–54.
  • Zhu Z, Zhang H, Yue J, Liu S, Li Z, Wang L. Antimicrobial efficacy of corneal cross-linking in vitro and in vivo for Fusarium solani: a potential new treatment for fungal keratitis. BMC Ophthalmol. 2018;18(1):65. doi:10.1186/s12886-018-0727-0.
  • Özdemir HB, Kalkancı A, Bilgihan K, Göçün PU, Öğüt B, Karakurt F, Erdoğan M. Comparison of corneal collagen cross-linking (PACK-CXL) and voriconazole treatments in experimental fungal keratitis. Acta Ophthalmol. 2019;97(1):e91–e96. doi:10.1111/aos.13829.
  • Vajpayee RB, Shafi SN, Maharana PK, Sharma N, Jhanji V. Evaluation of corneal collagen cross-linking as an additional therapy in mycotic keratitis. Clin Exp Ophthalmol. 2015;43(2):103–07. doi:10.1111/ceo.12399.
  • Erdem E, Harbiyeli II, Boral H, Ilkit M, Yagmur M, Ersoz R. Corneal collagen cross-linking for the management of mycotic keratitis. Mycopathologia. 2018;183(3):521–27. doi:10.1007/s11046-018-0247-8.
  • Chan TC, Agarwal T, Vajpayee RB, Jhanji V. Cross-linking for microbial keratitis. Curr Opin Ophthalmol. 2016;27(4):348. doi:10.1097/ICU.0000000000000271.
  • Tsugita A, Okada Y, Uehara K. Photosensitized inactivation of ribonucleic acids in the presence of riboflavin. Biochim Biophys Acta. 1965;103(2):360–63. doi:10.1016/0005-2787(65)90182-6.
  • Wang T, Peng Y, Shen N, Yu Y, Yao M, Zhu J. Photochemical activation increases the porcine corneal stiffness and resistance to collagenase digestion. Exp Eye Res. 2014;123:97–104. doi:10.1016/j.exer.2014.04.008.
  • Spoerl E, Mrochen M, Sliney D, Trokel S, Seiler T. Safety of UVA-riboflavin cross-linking of the cornea. Cornea. 2007;26(4):385–89. doi:10.1097/ICO.0b013e3180334f78.
  • Geffen N, Norman G, Kheradiya NS, Assia EI. Chlorhexidine gluconate 0.02% as adjunct to primary treatment for corneal bacterial ulcers. Isr Med Assoc J. 2009;11:664–68.
  • Martín-Navarro CM, Lorenzo-Morales J, Cabrera-Serra MG, Rancel F, Coronado-Alvarez NM, Pinero JE, Valladares B. The potential pathogenicity of chlorhexidine-sensitive Acanthamoeba strains isolated from contact lens cases from asymptomatic individuals in Tenerife, Canary Islands, Spain. J Med Microbiol. 2008;57(Pt 11):1399–404. doi:10.1099/jmm.0.2008/003459-0.
  • Rahman MR, Johnson GJ, Husain R, Howlader SA, Minassian DC. Randomised trial of 0.2% chlorhexidine gluconate and 2.5% natamycin for fungal keratitis in Bangladesh. Br J Ophthalmol. 1998;82(8):919–25. doi:10.1136/bjo.82.8.919.
  • Boral H, van Diepeningen A, Erdem E, Yagmur M, de Hoog GS, Ilkit M, Meis JF, Al-Hatmi AMS. Mycotic keratitis caused by Fusarium solani sensu stricto (FSSC5): A case series. Mycopathologia. 2018;183(5):835–40. doi:10.1007/s11046-018-0280-7.
  • Taj-Aldeen SJ, Salah H, Al-Hatmi AM, Hamed M, Theelen B, van Diepeningen AD, Boekhout T, Lass-Flörl C. In vitro resistance of clinical Fusarium species to amphotericin B and voriconazole using the EUCAST antifungal susceptibility method. Diagn Microbiol Infect Dis. 2016;85(4):438–43. doi:10.1016/j.diagmicrobio.2016.05.006.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.